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Prakash Satwani,1 Sejal Bavishi,1 Zhezhen Jin,2 Judith S. Jacobson,3 Courtney Baker,1
Deirdre Duffy,1 Leora Lowe,1 Erin Morris,1 Mitchell S. Cairo1,4,5Pediatric allogeneic stem cell transplant (AlloSCT) patients are at substantial risk of developing kidney injury
(KI), and KI contributes to transplant-related morbidity and mortality. We compared the estimated creatinine
clearance (eCrCl) at 1, 3, 6, 9, and 12 months post-AlloSCT in 170 patients following reduced toxicity condi-
tioning (RTC) versus myeloablative conditioning (MAC) to baseline. eCrCl was calculated using the Schwartz
equation. Patients with$50% drop in eCrCl from the baseline were considered to have KI. Patients received
tacrolimus and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis. The logistic
regression model was used for assessing risk factors for KI. Seventy-six patients (median age5 10.6 years) re-
ceived RTC AlloSCT; 94 patients (median age 5 8.5 years) received MAC AlloSCT. The incidence of KI at 1
month post-AlloSCT was significantly higher in MAC versus RTC AlloSCT (43/94 [45.7%] versus 13/76
[17.1%] P\.0001). There was no statistical difference in KI at 3, 6, 9, and 12 months post-AlloSCT between
the 2 conditioning groups. On multivariate analysis, only MAC was a significant risk factor for KI (odds radio
[OR] 3.44, 95% confidence interval [CI] 1.59-7.42, P 5 .002). In multivariate analysis for risk factors affecting
overall survival (OS), the following were statistically significant: MAC versus RTC (hazard ratio [HR] 2.66,
P 5 .0008), average versus poor-risk disease status (HR 2.09, P 5 .004), matched sibling donor (MSD) and
matched unrelated donor (MUD) versus umbilical cord blood (UCB) (HR 2.31, P 5 .013), no KI versus KI
(HR 2.00, P5 .005). In children, MAC is associated with significant risk of KI in the first month after transplant,
and KI in the first month post-AlloSCT is associated with a significantly decreased OS.
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Over the last 4 decades, there has been a significant
improvement in the field of allogeneic hematopoietic
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tablished as a potentially curative therapy for children
and adults with various malignant and nonmalignant
disorders [1]. The concept of AlloSCT as a treatment
option for hematologic malignancies has long been
based on the assumption that myeloablative doses of
cytotoxic therapy were required for both disease erad-
ication and host immunosuppression. However, over
the last decade, there has been a paradigm shift toward
curative potential of graft-versus-leukemia or tumor
(GVL/GVT) effect [2]. The concept behind reduced
toxicity conditioning AlloSCT (RTC AlloSCT) is
that instead of eradicating tumors through intensive/
toxic chemoradiation, the SCT donor’s immune cells
might be used for tumor eradication, relying on alloge-
neic GVT effects. Hence, elimination of high-dose cy-
totoxic therapy would allow medically infirm patients
to be treated with AlloSCT [2]. However, the success
of AlloSCT is limited by transplant-related mortality
Biol Blood Marrow Transplant 17:1472-1480, 2011 1473Kidney Injury Following AlloSCT(TRM). One potential factor that could lead or add to
TRM is kidney injury (KI) following AlloSCT.
The incidence of acute renal insufficiency in chil-
dren receiving myeloablative conditioning (MAC) fol-
lowing SCT ranges from 21% to 50% [3-5], and the
incidence of chronic renal insufficiency ranges from
11% to 62% [6]. Overall mortality rate is significantly
higher in patients with acute renal insufficiency after
AlloSCT [7]. Schrier and Parikh [7] compared the in-
cidence of acute renal injury in adult patients receiving
autologous myeloablative SCT versus nonmyeloabla-
tive AlloSCT and MAC AlloSCT and found the inci-
dence of acute KI to be 21% versus 40% versus
69%, respectively. Not surprisingly, an increase in
acute KI correlated with parallel increases in mortality
from 34% to 58% at 6 to 12months, as well as progres-
sive multiorgan involvement [7].
Patients with acute KI are at risk of chronic KI [8],
and patients who develop chronic KI are at increased
risk of mortality [9]. In a recently published study
from Fred Hutchinson Cancer Research Center, Seat-
tle, WA [10], the 30-year cumulative incidence of hy-
pertension in long-term survivors of pediatric
hematopoietic cell transplantation was 36%, and acute
KI was highly associated with risk of hypertension in
long-term survivors. Thus, prevention of acute KI fol-
lowing AlloSCT is needed to decrease early TRM as
well as to decrease long-term consequences.
Factors associated with KI in children following
AlloSCT include nephrotoxic medications, sepsis,
dehydration, sinusoidal obstruction syndrome, hyper-
tension, transplant-associated thromboticmicroangiop-
athy, viral and fungal infections, and/or its treatment,
and total-body irradiation conditioning regimen [3,5].
Understanding of risk factors associated with KI
might help to reduce the incidence of KI and may lead
to decreases in short- and long-term morbidity and
mortality.
There have been a few prospective studies in chil-
dren and adults as well as retrospective studies in adults
regarding the incidenceof acuteKI.Although there have
been a few retrospective studies in adults comparing KI
followingMACandRTCAlloSCT, there is a paucity of
parallel data on incidence of KI in children following
RTC versus MAC AlloSCT. In the current study, we
compared the incidence of KI and risk factors and mor-
tality in children following MAC and RTC AlloSCT.MATERIALS AND METHODS (DESCRIBED
IN PART IN OUR PREVIOUS PUBLICATIONS)
[11,12]
Patients included in this retrospective analysis
included all consecutive children and adolescents
who received a RTC or MAC AlloSCT at the
New York-Presbyterian Morgan Stanley Children’sHospital between January 2001 and December 2007.
Indications for transplant included a variety of malig-
nant and nonmalignant conditions. Allogeneic sources
of stem cells included bone marrow (BM), peripheral
blood stem cells (PBSC), and umbilical cord blood
(UCB). All patients were on clinical protocols for Al-
loSCT approved by the institutional review board at
Columbia University Medical Center, and all research
protocols were in compliance with the Declaration of
Helsinki.
HLATyping and Stem Cell Source
HLA-A and HLA-B antigen typing was performed
by intermediate resolution molecular testing, and
HLA-C, HLA-DRB1, and HLA-DQB1 allele typing
was determined by hybridization of polymerase chain
reaction (PCR)-amplified DNA with sequence-
specific oligonucleotide probes, as we previously de-
scribed [11]. Confirmatory typing was performed at
Columbia University Medical Center. The criteria for
graft matching included at least 4-5/6 loci for UCBT
or 8/10 or greater for unrelated donor PB/BM and 5-
6/6 HLA matched sibling. Transplants were classified
as HLA-mismatched with 1 or 2 differences if dispar-
ities were detected in HLA-A, HLA-B, antigens or
HLA-C, HLA-DRB1, and HLA-DQB1 alleles.
Conditioning Regimens
Specific conditioning regimens were protocol
driven and disease specific. The RTC regimen included
patients who received busulfan (6.4-8 mg/kg), fludara-
bine (150-180 mg/m2) 6 ATG (n 5 40); or busulfan
(12.8-16mg/kg), fludarabine (150-180mg/m2)6 alem-
tuzumab (54 mg/m2) (n 5 20); and cyclophosphamide
60 mg/kg, fludarabine (150-180 mg/m2) (n 5 16).
The MAC regimen included busulfan (12.8-16 mg/
kg), cyclophosphamide (120-200 mg/kg), melphalan
(135 mg/m2) 6 antithymocyte globulin (ATG) (n 5
50); or total body irradiation (TBI), cyclophosphamide
(120-200 mk/kg), melphalan (135 mg/m2) 6 ATG
(n 5 44).
Graft-versus-Host Disease
Graft-versus-host disease prophylaxis
and grading
Acute graft-versus-host disease (aGVHD) prophy-
laxis in the majority of patients consisted of tacrolimus
starting at 0.03 mg/kg/day as continuous intravenous
(i.v.) infusion or 0.12 mg/kg orally (p.o.) twice a day
with dosage adjustment to maintain blood levels be-
tween 5 and 20 ng/mL and mycophenolate mofetil
(MMF) at 15-30 mg/kg every 6 to 12 hours either
p.o. or i.v., as we have previously described [13,14].
Tacrolimus was started either on the first day of
conditioning regimen or day 21 and MMF began on
1474 Biol Blood Marrow Transplant 17:1472-1480, 2011P. Satwani et al.day 11. Tacrolimus and/or MMF were tapered if
patients had equal to or less than grade II aGVHD
on day 130 for malignant diseases and day 1180 for
nonmalignant diseases [14]. Acute GVHD and chronic
GHVD (cGVHD) were graded according to Seattle
criteria [15]. Patients who received unrelated AlloSCT
also received methotrexate (MTX) 15 mg/m2 adminis-
tered i.v. on day11 followed by MTX 10 mg/m2 slow
i.v. push on days 13, 16, and 111.
Infection Prophylaxis and Supportive Care
All patients were hospitalized in protective isola-
tion defined as single hospital rooms with high effi-
ciency particulate air filtration system and reverse
isolation requiring strict hand degerming and mask
use by staff for unrelated hematopoietic SCT
(HSCT) patients. All patients received sargramostim
(250 mg/m2/day) i.v. daily from day 0 until the white
blood cells (WBCs) reached $300/mm3  2 days
and then were switched to filgrastim (10 mg/kg/day) ei-
ther i.v. or subcutaneously until an absolute neutrophil
count of $2500/mm3 was achieved for 3 days as we
previously described [16]. Herpes simplex virus
(HSV) prophylaxis consisted of acyclovir (250 mg/
m2) i.v. every 8 hours from day 25 until engraftment
and equal to or less than grade II mucositis. Pneumocys-
tis carinii prophylaxis consisted of trimethoprim/sulfa-
methoxazole until day 22 and then resumed 3 times
weekly after myeloid engraftment. Patients unable to
tolerate trimethoprim/sulfamethoxazole received i.v.
pentamidine prophylaxis every 2 weeks. Fungal pro-
phylaxis consisted of liposomal amphotericin B (3
mg/kg/day) i.v. starting on day 0 through day 1100,
as we previously described [17]. Cytomegalovirus
(CMV) prophylaxis was administered as we have re-
cently described [18]. Briefly, patients with risk of ac-
quiring CMV infection (CMV1 donor and/or
recipient) after achieving an absolute neutrophil count
.750/mm3 after AlloSCT received prophylaxis with
foscarnet (90 mg/kg/dose) every other day, alternating
with ganciclovir (5 mg/kg/dose) every other day until
day 1100.
Kidney Function Monitoring
In all patients, serum creatinine was measured
daily in the inpatient unit for the first 30 days, and
those patients who were discharged before day 130
had serum creatinine measured 2 or 3 times a week.
TRM was defined as death because of any cause
other than disease relapse.
Poor-risk malignant patients were defined as: che-
moresistant malignant disease, third complete remis-
sion or greater, induction failure, progressive disease,
and/or receiving second allograft. All other patients
with malignant diseases and nonmalignant diseases
were defined as average risk.Definitions
Estimated creatinine clearance (eCrCl) was calcu-
lated using the Schwartz equation [19]. We compared
eCrCl at 1, 3, 6, 9, and 12 months post-AlloSCT to
baseline (#2 weeks pre-AlloSCT).
Kidney injury was defined as $50% decrease in
eCrCl from the baseline pretransplant value [20].
Statistical Methods
The continuous variables were summarized by
mean 6 standard deviation, and categoric variables
were summarized by percentage. The comparisons be-
tween 2 treatment groups were done by t-test for con-
tinuous variables and by chi-square test for categoric
variables. For KI at 1, 3, 6, and 12 months following
AlloSCT the eCrCl was compared to the baseline
eCrCl measured prior to the start of conditioning reg-
imen. The logistic regression model was used to inves-
tigate the effects of treatment on the first month KI.
The multivariate logistic regression model was built
with those factors significant at level 0.2 in the univar-
iate analysis. Survival was examined with the Kaplan-
Meier method, and comparison of survival between
groups was carried out by the log-rank test. In addi-
tion, the Cox proportional hazards model was used
for the analysis of risk factors on survival, andmultivar-
iate analysis was carried out based on those factors sig-
nificant at level 0.2 in the univariate analysis. Patients
who were alive were censored at subsequent trans-
plant, or end of follow-up. Risk factors analyzed for
KI were age, gender, baseline eCrCl, CMV risk status,
fungal infection, disease status disease type (malignant
versus nonmalignant), veno-occlusive disease (VOD),
UCB, MAC, and stem cell source, liver dysfunction
(alanine aminotranferase .5 times of upper limit of
normal and bilirubin .2 mg/dL) in the first 30 days
post-AlloSCT and use of foscarnet in the first 30
days post-AlloSCT; and risk factors analyzed for over-
all survival (OS) were age, gender, CMV risk status,
disease type and disease status, VOD, fungal infec-
tions, stem cell source, bacterial and viral infections,
and aGVHD and cGVHD. The SAS 9.2 was used
for data analysis.RESULTS
Patients and Demographics
A total of 170 patients received AlloSCT within
the study time period (106 male, 64 female; age:
9.5 6 6.55 years). The RTC group contained 76 pa-
tients (age 10.666 6.66 years) of whom 44 (57.8%) re-
ceived transplants for malignant conditions (acute
myeloid leukemia/myelodysplastic syndrome n 5 14;
neuroblastoma n 5 10; Hodgkin lymphoma n 5 9;
chronic myeloid leukemia n 5 5; non-Hodgkin
Biol Blood Marrow Transplant 17:1472-1480, 2011 1475Kidney Injury Following AlloSCTlymphoma n 5 6), and 32 (42.2%) for nonmalignant
conditions (hemoglobinopathies n 5 11; severe aplas-
tic anemia n5 12; immunodeficiency disorders n5 3;
histiocytic disorders/hemophagocytic lymphohistio-
cytosis n 5 3; metabolic disorder n 5 3). The MAC
group contained 94 patients (age 8.5 6 6.33 years),
64 (67%) received transplants for malignant condi-
tions (acute myeloid leukemia/myelodysplastic syn-
drome n 5 28; acute lymphoblastic leukemia n 5 30;
non-Hodgkin lymphoma n 5 4; neuroblastoma n 5
2), and 30 (33%) received transplants for nonmalig-
nant conditions (hemoglobinopathies n 5 9; histio-
cytic disorders/hemophagocytic lymphohistiocytosis
n 5 8; severe aplastic anemia n 5 10; and immunode-
ficiency disorders n 5 3). There was no statistical dif-
ference when we compared gender (P 5 .07), CMV
risk status (P 5 .96), and patients with malignant dis-
eases (P 5 .17), between MAC versus RTC AlloSCT.
However, children in the RTC AlloSCT group were
older (P5 .03), and there were more children who re-
ceivedUCB (P\ .001) and were in the poor-risk group
(P 5 .009) in the MAC AlloSCT group (Table 1).
Donor source
The donor source in the RTC regimen consisted
of UCB (n 5 36), HLA matched siblings (n 5 31)
and unrelated donors (n5 9). Among patients who re-
ceived a MAC AlloSCT the donor source consisted of
UCB (n 5 74), HLA-matched siblings (n 5 15), and
unrelated donors (n 5 5).Table 1. Demographics of Pediatric AlloSCT Recipients Who Rece
Characteristic All
n 5 170
Age (years) 9.5 ± 6.55
Gender
Male 106 (62.3%)
Female 64 (37.7%)
Disease type
Malignant 108 (63.2%)
Nonmalignant 62 (36.8%)
Disease status
Average-risk group 135 (79.3%)
Poor-risk group 35 (20.7%)
CMV risk status
Donor or recipient seropositive 116 (68.2%)
Donor and recipient seronegative 54 (31.8%)
Donors
MSD 46 (27%)
MUD 14 (8.2%)
UCB 110 (64.7%)
Pre-AlloSCTestimated CrCl*
#70 1 (0.6%)
71-100 35 (20.6%)
>100 134 (78.8%)
Median 133.9
Mean 139.5 ± 42.8
CMV indicates cytomegalovirus; MSD, matched sibling donor; MUD, match
conditioning; RTC, reduced toxicity conditioning.
*CrCl 5 mL/min per 1.72 m2.Engraftment
The time to neutrophil and platelet engraftment in
the RTC AlloSCT group was 19.7 6 10.4 days and
43.36 37.3 days, respectively. The time to neutrophil
and platelet engraftment in the MAC AlloSCT group
was 18.4 6 11.3 days and 30.5 6 26.9 days, respec-
tively.
GVHD
The probability of developing aGVHD grade
II-IV was 30.1% (CI95 19.6-40.7) in RTC versus
MAC AlloSCT 52.8% (CI95 42.3-63.4) P 5 .003.
The probability of developing cGVHD in RTC versus
MAC AlloSCT was 21.6% (CI95 10.8-32.4%) versus
15.9% (CI95 6.6%-25.2%) P 5 .431 (ns).
Kidney injury
Patients were considered to have KI if they had
$50% drop in eCrCl when compared to baseline
eCrCl performed 2 weeks prior to starting the condi-
tioning regimen. eCrCl 2 weeks prior to starting con-
ditioning regimen between MAC and RTC AlloSCT
group was comparable (P 5 .31). The median eCrCl
was 139.8 mL/min/1.72 m2 and mean eCrCl was
145.1 6 47.0 mL/min/1.72 m2, in the MAC AlloSCT
group; and median eCrCl was 131.5 mL/min/1.72 m2,
and mean eCrCl was 132.56 36.2 mL/min/1.72 m2 in
the RTC AlloSCT group. Estimated CrCl (mL/min
per 1.72 m2) of 71 to 100 was noted in 17% versusived RTC versus MAC
MAC RTC P Value
n 5 94 n 5 76 ___
8.49 ± 6.33 10.66 ± 6.66 .031
.074
53 (56.4%) 53 (69.7%)
41 (43.6%) 23 (30.3%)
.230
64 (68.1%) 45 (59.2%)
30 (31.9%) 31 (40.8%)
.11
68 (72%) 67 (88.2)
26 (28.0%) 9 (11.8%)
64 (68.1%) 52 (68.4%) .963
30 (31.9%) 24 (31.6%)
15 (16.0%) 31 (40.7%) <.001
5 (5.3%) 9 (11.8%)
74 (78.7%) 36 (48.6%)
1 (1%) 0 .307
16 (17%) 19 (25%)
78 (81.9%) 57 (75%)
139.8 131.5
145.1 ± 47 132.5 ± 36.2
ed unrelated donor; UCB, umbilical cord blood; MAC, myeloablative
Table 3. Univariate Analysis for Risk Factors Associated with
OS Following RTC versus MAC in Pediatric AlloSCT
Recipients
Variable Ratio Confidence Limits P Value
Age 1.009 0.973 1.047 .613
Gender
Female 1
Male 0.788 0.486 1.280 .336
CMV risk status
D or R seropositive 1
D and R seronegative 0.933 0.571 1.525 .782
Malignant disease
No 1
Yes 1.150 0.703 1.880 .578
Baseline eCrCI 1.003 0.997 1.008 .394
Disease risk status
Average 1
Poor 2.735 1.673 4.471 <.0001
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group, respectively, and eCrCl .100 was noted in
81.9% versus 75% of patients in the MAC versus
RTC AlloSCT group, respectively (Table 1).
Thirty days following AlloSCT, 33% patients de-
velopedKI. The incidence of KI at 1month was 45.7%
inMACAlloSCT versus 17.1% in RTCAlloSCT, P\
.0001. However, the incidence of KI at 3 months was
55% (59% in MAC AlloSCT versus 50.7% in RTC
AlloSCT, P 5 .3) (Table 2). The incidence of KI at
6 months was 58% (66.7% in MAC AlloSCT versus
50% in RTC AlloSCT, P 5 .05), and the incidence
of KI at 12 months was 36% (46% in MAC AlloSCT
versus 28.9% in RTC AlloSCT, P 5 .10). The inci-
dence of KI was consistently higher in children who
received MAC AlloSCT when compared to RTC
AlloSCT during the first year post-AlloSCT. KI was
statistically significantly higher at 1 month following
AlloSCT. We subsequently performed an analysis
comparing the incidence of .75% drop in eCrCL at
1 month between MAC versus RTC AlloSCT; 15/94
(16.0%) MAC AlloSCT and 2/76 (2.6%) RTC
AlloSCT patients developed .75% drop in eCrCL
from the baseline (P 5 .004).
During the first year post-AlloSCT, 25/170
(14.7%) required continuous renal replacement ther-
apy (CRRT) with continuous veno-venous hemofiltra-
tion. The incidence for CRRT was 17/94 (18%) for
MAC AlloSCT and 8/76 (11%) for RTC AlloSCT
(P 5 ns); 24/25 of the patients requiring CRRT
ultimately died. Among 17 patients receiving CRRT
in the MAC AlloSCT group, 15/17 (88%) deaths
were related to TRM and 2/17 (12%) were related to
disease relapse. Among 8 patients receiving CRRT in
the RTC AlloSCT group, 1 patient survived, and 4/7
(57%) deaths were related to TRM and 3/7 (43%)
deaths were disease related.Table 2. Incidence of KI Following RTC versus MAC in
Pediatric AlloSCT Recipients
Time
Drop
in eCrCL MAC-AlloSCT RTC-AlloSCT P Value
1 month n 5 94 n 5 76 <.0001
<50% 51 (54.3%) 63 (82.9%)
$50% 43 (45.7%) 13 (17.1%)
3 months n 5 78 n 5 73 .306
<50% 32 (41.0%) 36 (49.3%)
$50% 46 (59.0%) 37 (50.7%)
6 months n 5 63 n 5 70 .052
<50% 21 (33.3%) 35 (50.0%)
$50% 42 (66.7%) 35 (50%)
9 months n 5 48 n 5 58 .088
<50% 21 (43.7%) 35 (60.3%)
$50% 27 (56.3%) 23 (39.7%)
12 months n 5 37 n 5 52 .098
<50% 20 (54.0%) 37 (71.1%)
$50% 17 (46.0%) 15 (28.9%)
eCrCl indicates estimated creatinine clearance; MAC, myeloablative
conditioning; RTC, reduced toxicity conditioning.Survival analysis
Kidney injury and various other transplant-related
factors could lead tomortality in patients following Al-
loSCT. We performed univariate analysis for risk fac-
tors associated with OS following RTC versus MAC
AlloSCT; age, gender, CMV risk status, disease type,
and VOD, fungal infections, bacterial and viral infec-
tions, and cGVHD were not statistically significant.
However, disease status, UCB as a stem cell source,
MAC regimen, aGVHD, and KI at 1 month were sta-
tistically significant on univariate analysis (Table 3).
On multivariate analysis, poor-risk disease status (haz-
ard ratio [HR] 5 2.008, 95% confidence interval [CI]
1.261-3.458, P 5 .0042), UCB as a stem cell source
(HR 5 2.312, 95% CI 1.194-4.478, P 5 .0129),
MAC regimen (HR 5 2.666, 95% CI 1.499-4.743,
P 5 .0008), and KI at 1 month (HR 5 2.000, 95%CI
1.230-3.252, P 5 .0052) were independently associ-
ated with poor OS (Table 4).VOD
No 1
Yes 1.921 0.696 5.303 .208
Fungal infection
No 1
Yes 1.276 0.633 2.574 .496
Stem cell source
MSD/MUD 1
UCB 3.161 1.656 6.034 .0005
Acute GVHD*
No 1
Yes 1.652 1.005 2.714 .048
Chronic GVHD*
No 1
Yes 0.628 0.225 1.757 .376
Conditioning
RTC 1
MAC 3.839 2.214 6.650 <.0001
1 month
Drop in eCrCl
<50% 1
$50% 2.425 1.507 3.900 .0003
CMV indicates cytomegalovirus; D/R, donor/recipient; VOD, veno-
occlusive disease; MSD/MUD, matched sibling donor/matched unrelated
donor; UCB, umbilical cord blood; GVHD, graft-versus-host disease.
*Time-dependent analysis.
Table 4. Multivariate Analysis for Significant Risk Factors
Affecting OS Following RTC versus MAC in Pediatric AlloSCT
Recipients
Variable
Hazard
Ratio
95% Hazard Ratio
Confidence Limits P Value
Group
RTC 1
MAC 2.666 1.499 4.743 .0008
Risk
Average 1
Poor 2.088 1.261 3.458 .0042
Donor source
MSD and MUD 1
UCB 2.312 1.194 4.478 .0129
Acute GVHD*
No 1
Yes 1.282 1.230 3.252 .3356
1 month
Drop in eCrCl
<50% 1
$50% 2.000 1.230 3.252 .0052
MAC indicates myeloablative conditioning; RTC, reduced toxicity condi-
tioning; MSD, matched sibling donor; MUD, matched unrelated donor;
UCB, umbilical cord blood; eCrCl, estimated creatinine clearance.
*Time-dependent analysis.
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onOS.We further analyzed our data to determine that
KI was associated with an increase in TRM. In univar-
iate analysis, KI at 1 month was associated with
increased risk of TRM, odds ratio 2.065 (CI95 0.976-
4.368, P 5 .0578).
Univariate and multivariate analysis for KI
at 1 month
We performed a univariate analysis with various
factors (age, gender, baseline eCrCl, CMV risk
status, fungal infection, disease status, disease typeFigure 1. Probability of OS following KI at 1 month versus no KI at 1[malignant versus nonmalignant], VOD, liver dysfunc-
tion, foscarnet, UCB, MAC, and stem cell source) that
could result in KI at 1 month (Table 5). On univariate
analysis, poor disease risk status (odds ratio [OR] 5
2.325, 95% CI 1.087-4.972, P 5 .030), VOD (OR 5
8.689, 95% CI 0.948-79.65, P 5 .056), UCB
(OR 5 1.782, 95% CI 0.885-3.591, P 5 .106), and
MAC (OR 5 4.086, 95% CI 1.985-8.410, P 5 .0001),
were significant risk factors of KI at 1 month post-
AlloSCT. On multivariate analysis with the significant
risk factors, only MAC (OR 5 3.438, 95% CI 1.594-
7.418, P5 .002) remained as significant (Table 6).DISCUSSION
AlloSCT has curative potential for children with
malignant and nonmalignant diseases. However, Al-
loSCT is associated with short-term and long-term
morbidity and mortality. Acute and chronic KI is an
important cause of morbidity and can lead to mortality
following AlloSCT. Understanding causes for KI is of
paramount importance to prevent KI. Reduction in KI
might lead to improvement in AlloSCT outcomes.
There are no uniform definitions and time points
for assessment of KI following AlloSCT [21], which
makes comparisons of various studies difficult and
hampers our ability to perform meaningful compara-
tive analysis. Therefore, there is a need for develop-
ment of uniform guidelines to assess kidney function
following AlloSCT. Schwartz equation is 1 of the
most common methods of estimating changes in acute
renal function in critically ill pediatric patients [20,22].
Similarly, there are also various definitions used
for chronic KI [23-26]. Because we assessed KI
longitudinally for 1 year, we used the consistentmonth in pediatric allogeneic stem cell transplantation recipients.
Table 5. Univariate Analysis for Risk Factors Associated with
KI at 1 Month in Pediatric AlloSCT Recipients
Variable
Odds Risk
Ratio
95% Confidence
Limits P Value
Age 1.017 0.969-1.068 .494
Gender
Female 1.0
Male 1.270 0.651-2.478 .484
Disease risk status
Average 1.0
Poor 2.325 1.087-4.972 .030
Malignancy
Yes 1.0
No 1.05 0.539-2.044 .886
CMV risk status
D or R seropositive 1.0
D and R seronegative 0.679 0.345-1.334 .261
Stem cell source
MSD/MUD 1
UCB 1.782 0.885-3.591 .106
Conditioning
RTC 1
MAC 4.086 1.985-8.410 .0001
Baseline eCrCI 1.004 0.997-1.011 .293
Fungal infection
No 1.0
Yes 1.417 0.543-3.693 .476
VOD
No 1
Yes 8.689 0.948-79.65 .056
Foscarnet
No 1
Yes 1.195 0.630-2.268 .586
ALT* $5  ULN
No 1
Yes 0.943 0.361-2.464 .905
Bilirubin* >2 mg/dL
No 1
Yes 1.438 0.719-2.874 .304
CMV indicates cytomegalovirus; D/R, donor/recipient; VOD, veno-
occlusive disease; MSD/MUD, matched sibling donor/matched unrelated
donor; UCB, umbilical cord blood; RTC, reduced toxicity conditioning;
MAC, myeloablative conditioning; foscarnet therapy in first 30 days
post-AlloSCT, ALT, alanine aninotransferase; ULN, upper limit of
normal.
*ALT and biliubin values in first 30 days post-AlloSCT.
Table 6. Multivariate Analysis for Risk Factors Associated
with KI at 1 Month in Pediatric AlloSCT Recipients
Variable
Odds Risk
Ratio
95% Confidence
Limits P Value
Disease risk status
Average 1
Poor 1.760 0.777-3.988 .175
VOD
No 1
Yes 4.892 0.518-46.18 .166
Stem cell source
MSD/MUD 1
UCB 1.062 0.484-2.331 .881
Conditioning
RTC 1
MAC 3.438 1.594-7.418 .002
VOD indicates veno-occlusive disease; MSD/MUD, matched sibling do-
nor/matched unrelated donor; UCB, umbilical cord blood; RTC, re-
duced toxicity conditioning; MAC, myeloablative conditioning.
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could be compared at various time points.
In the current retrospective study, we compared the
incidence of KI in children receiving RTC versusMAC
AlloSCT over a period of 1 year. One month following
AlloSCT, a significantly higher number of children
had KI after MAC AlloSCT when compared to RTC
AlloSCT. One month following AlloSCT, 33% of pa-
tients developed KI. In a study published by Van Why
et al. [5], the incidence of acute renal insufficiency in 64
children who underwent MAC AlloSCT was 50%,
which is comparable to the incidence of KI in our chil-
dren following MAC AlloSCT. The incidence of KI in
the MAC AlloSCT group in our study at 1, 3, and 6
months was 45.7%, 59%, and 66%, respectively. How-
ever, a retrospective study published by Kist-van
Holthe et al. showed a 34% incidence of acute renal
insufficiency in children (n 5 142) following MAC
AlloSCT [4]. In a follow-up prospective study fromthe same group, the incidence of acute renal insuffi-
ciency in 66 children following MAC AlloSCT was
21% [3], with the decrease inKI attributed to aggressive
monitoring of renal function. Incidence of KI in our
study is relatively higher when compared to the
Kist-van Holthe et al. study, and 1 probable reason
for that could be our aggressive antifungal and antiviral
prophylaxis with liposomal amphotericin B and foscar-
net, respectively. Based on our analysis, we have modi-
fied our antifungal prophylaxis by decreasing the dose
(1.5 mg/kg from 3 mg/kg) and duration of liposomal
amphotericin-B: after 45 days following AlloSCT lipo-
somal, amphotericin-B is replaced by micafungin [27].
Maribavir or CMX 001 (Chimerix) could be a potential
alternative to foscarnet and ganciclovir for CMV pro-
phylaxis in high-risk patients at risk for CMV reactiva-
tion and disease.
In our study, the incidence of CRRT was 18% for
MAC AlloSCT and 11% for RTC AlloSCT. The re-
ported incidence of CRRT after MAC in pediatric pa-
tients is variable between 5% and 24%. The incidence
of CRRT in pediatric patients after RTC AlloSCT has
never been reported. However, in adult RTCAlloSCT
the incidence of CRRT is 3% to 4% [28]. In our study,
OS of children requiring CRRTwas dismal (4%). Var-
ious single-center studies in children and adults have
reported OS rates between 0% and 45% in patients
requiring CRRT after MAC AlloSCT [29-31].
Recently, a report from the prospective pediatric
CRRT registry group demonstrated that 45% of chil-
dren post-AlloSCT survived to get discharged from
the intensive care unit [29]. These results are encour-
aging, and in this study, 88% of the patients received
CRRT because of fluid overload. It seems that investi-
gators in this observational multicenter study were ini-
tiating CRRT early in order to prevent severe fluid
overload. In a recent observational study by Suther-
land et al. [32], children who developed $20% fluid
overload at CRRT initiation had significantly higher
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fluid overload (43.1%) and those with \10% fluid
overload (29.4%). This study also demonstrated
a 3% increase in mortality for each 1% increase in se-
verity of fluid overload and patients with $20% fluid
overload had an adjusted mortality odds ratio of 8.5
(95% CI, 2.8-25.7). Aggressive and appropriate man-
agement of fluid balance is critical for children follow-
ing AlloSCT.
Kidney injury is not only associated with TRM,
but also associated with inferior OS. Kidney injury af-
ter RTC and MAC AlloSCT is an independent pre-
dictor of relapse and TRM. In our study, at 3 years,
OS was significantly higher in patients without KI
at 1 month versus KI at 1 month (75% versus 45%,
P\ .0001). In a study by Lopes et al. [33], adult pa-
tients with KI following RTC AlloSCT experienced
poorer long-term survival. In this study 5-year OS
of KI patients was 41.6%, compared with 67.1% for
those who did not develop KI (P 5 .028). In another
study, Kersting et al. [34] reported similar findings
that adult patients following RTC AlloSCT with KI
had significantly higher mortality compared to no
acute KI (P 5 .006). In a meta-analysis by Parikh
et al. [35], in adult patients after MAC AlloSCT there
was doubling in relative risk (RR 5 2.31; CI [1.47-
3.65], P\ .01) of death in patients who had at least
a doubling of serum creatinine from baseline. Data
comparing impact of KI versus no KI in children fol-
lowing RTC or MAC AlloSCT is very limited, and
our study highlights the critical nature of impact of
KI on TRM and OS.
When assessing the risk of KI in children undergo-
ing AlloSCT, one needs to consider various other fac-
tors beyond the conditioning regimen. Compared with
heavily pretreated patients, patients who undergo Al-
loSCT for nonmalignant disease potentially have
a lower risk of KI post-AlloSCT because of an intact
immune system, absence of chemotherapy-related
KI, and lack of significant end-organ damage. Donor
source also may have an impact on the risk of KI. Com-
pared to children undergoing AlloSCTwith UCB (de-
layed immune reconstitution) or an unrelated donor
(increased risk of GVHD), children undergoing
HLA-matched sibling AlloSCT have a lower risk of
GVHD and relatively faster immune reconstitution,
which may lead to a decreased incidence of fungal
and viral infections. The infections and/or its treat-
ment may lead to KI. In univariate analysis for risk fac-
tors for KI, poor risk disease status, VOD, UCB
transplant, and MAC were statistically significant. In
our multivariate analysis, we controlled for individual
risk factors, and were unable to demonstrate the indi-
vidual impact of these factors on the risk of KI at 1
month post-AlloSCT other than MAC, that was a sig-
nificant independent risk factor for KI at 1 month. We
also performed a multivariate analysis for significantrisk factors affecting OS following AlloSCT. Myeloa-
blative conditioning, poor-risk disease status, UCB
transplant, and KI at 1 month were independent pre-
dictors of poor survival. However, the primary goal
of this study was to compare KI between RTC versus
MAC AlloSCT and not the OS.
The major limitation of this retrospective study is
the small sample size in both groups, lack of prospec-
tive randomization, similar donor sources, and disease
risk status. Because subjects were heterogeneous in
terms of underlying disease, conditioning regimen,
and hematopoietic stem cell donor sources, these pre-
liminary analyses should be replicated in additional
studies of children with more homogenous diagnoses
and cell sources. Despite these limitations, we believe
that the central conclusions are valid. The fact that
this study was conducted at a single institution ensures
that consistent policies and protocols were followed in
terms of anti-infection prophylaxis, isolation precau-
tions, and diagnosis of GVHD, VOD, and infections.
In summary, a significant number of children sus-
tain KI following AlloSCT. MAC AlloSCT is a signif-
icant risk factor for KI at 1 month. Kidney injury may
lead to an increase in TRM and impact OS. Patients
undergoing AlloSCT, especially MAC AlloSCT,
should have close monitoring of kidney function, judi-
cious use of nephrotoxic medication and drug level
monitoring, and early intervention of fluid overload.
There is need for prospective studies for prevention
of KI, validation of KI biomarkers, and role of early
initiation of CRRT.ACKNOWLEDGMENTS
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